NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » GlaxoSmithKline back to previous page show list

GlaxoSmithKline

»
address: Contact Information:
GlaxoSmithKline,
Glaxo Wellcome UK Ltd.,
Stockley Park West,
Uxbridge,
Middlesex, UB11 1BT
contact: General Enquiries:
Tel: 020 8990 9000
Fax: 020 8990 4321
key person: Jean-Pierre Garnier - Chief Executive Officer
Rupert Bondy - Senior Vice President and General Counsel
John Clarke - President, Consumer Healthcare
Marc Dunoyer - President, Pharmaceuticals Japan
Russell Greig - President,

trunover in millions USD: 45525
R & D turnover in millions USD: 6810
NET profit: 15364
year of financial results: 2006
employees: 100

active in China: YES
partner in China: GlaxoSmithKline (China) Investment Co., Ltd.
■ Sino-American Tianjin Smith Kline & French Laboratories Ltd.
■ GlaxoSmithKline (Tianjin) Co. Ltd.
■ GlaxoSmithKline Pharmaceuticals (Suzhou) Ltd.
■ GlaxoSmithKline Biological

SFDA approved: NO

Approvals:
GLP: YES
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: YES
R&D: YES
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: YES
Batch Release: YES

Clinical trials:
Run/Manage: YES
Data management: YES
Support Labs: YES

Non clinical & preclinical:
Animal Testing: GLP: YES
New materials Safety Assessment: YES
Pharmaceuticals: YES
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: YES

test:
R&D: YES
 

We are the only pharmaceutical company to tackle the World Health Organization’s three ‘priority’ diseases – HIV/AIDS, tuberculosis and malaria.

Headquartered in the UK and with operations based in the US, we are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.  We must help developing countries where debilitating disease affects millions of people and access to life-changing medicines and vaccines is a problem.

As a company with a firm foundation in science, we have a flair for research and a track record of turning that research into powerful, marketable drugs. Every hour we spend more than £300,000 (US$562,000) to find new medicines.

We produce medicines that treat six major disease areas – asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, we are a leader in the important area of vaccines and are developing new treatments for cancer.

GSK at a glance

Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer

We are a research-based pharmaceutical company

We are the only pharmaceutical company to tackle the three "priority" diseases identified by the World Health Organization: HIV/AIDS, tuberculosis and malaria

Our business employs over 100,000 people in 116 countries

We make almost four billion packs of medicines and healthcare products every year

Over 15,000 people work in our research teams to discover new medicines

We screen about 65 million compounds every year in our search for new medicines

We supply one quarter of the world's vaccines and by the end of 2005 we had 25 vaccines in clinical development

In 2005 we donated 136 million albendazole tablets to help elimitate lymphatic filariasis (elephantiasis)

In 2005 we shipped 126 million tablets of preferentially-priced Combivir and

 Epivir (our HIV treatments) to developing countries

Jean-Pierre Garnier

- Chief Executive Officer

Rupert Bondy

- Senior Vice President and General Counsel

 John Clarke - President, Consumer Healthcare

Marc Dunoyer

- President, Pharmaceuticals Japan

Russell Greig

- President, Pharmaceuticals International

Julian Heslop

- Chief Financial Officer

Bill Louv Senior Vice President, Information Technology and Chief Information Officer

Dan Phelan - Senior Vice President, Human Resources

David Pulman

- President, Global Manufacturing and Supply

Moncef Slaoui

- Chairman, Research & Development

David Stout

- President, Pharmaceutical Operations

Chris Viehbacher has served as President, US Pharmaceuticals, GlaxoSmithKline since January 2003. Andrew Witty - President, Pharmaceuticals Europe

The Corporation
GlaxoSmithKline is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.

GlaxoSmithKline was established in December 2000 from the equal merger of Glaxo Wellcome and SmithKline Beecham. The two companies, themselves the products of mergers in the past, originally began as individual, private companies founded during the 19th century. By the end of the 20th century, both companies had already become world-class pharmaceutical corporations in their own right. Due to the successful merger of these two global pharmaceutical giants, GlaxoSmithKline is well positioned to become the indisputable leader of the pharmaceutical industry worldwide.

GlaxoSmithKline has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. 

GlaxoSmithKline has 82 manufacturing sites in 37 countries that supply products to the global markets. GlaxoSmithKline has over 100,000 highly skilled and dedicated employees worldwide.

CHINA

Since the 1980s, GlaxoSmithKline has actively invested in China by contributing state-of-the-art pharmaceutical technologies, innovative products, new business models, modern management concepts, and sales & marketing skills.

Since the completion of the global merger between Glaxo Wellcome and SmithKline Beecham in December 2000, GlaxoSmithKline has become one of the world's leading pharmaceutical companies. In 2002, GlaxoSmithKline (China) Investment Co. Ltd. was officially established and became one of the largest multinational pharmaceutical companies in China.

Among its major business units in China, Prescription Medicines and Vaccines are headquartered in Shanghai, Over-the-Counter (OTC) Medicines is headquartered in Tianjin, and Consumer Healthcare is headquartered in Hong Kong. Beijing is also the base for the holding company GlaxoSmithKline (China) Investment Co. Ltd.

GlaxoSmithKline was one of the first foreign pharmaceutical companies to establish successful joint ventures in China. To date, nearly twenty years after its initial investment in China, GlaxoSmithKline has established five legal entities encompassing four manufacturing facilities (three are joint ventures) with a total registered capital of over US$230 million in China.

GlaxoSmithKline China has established office in 29 major cities (including Hong Kong) with 2,800 employees nationwide. The various companies continue to create jobs and provide training for business managers and professional staff in the pharmaceutical industry, as well as provide business opportunities to local partners and medical professionals.

GlaxoSmithKline (China) Investment Co., Ltd.
Sino-American Tianjin Smith Kline & French Laboratories Ltd.
GlaxoSmithKline (Tianjin) Co. Ltd.
GlaxoSmithKline Pharmaceuticals (Suzhou) Ltd.
GlaxoSmithKline Biological Shanghai Ltd.

................................................................................................................................................. Beijing:
8/F North Tower, Kerry Centre
1 Guang Hua Road,Chaoyang District,Beijing 100020
Tel: +86 10 8529 6868
Fax: +86 10 8529 6767 .................................................................................................. Shanghai:
6F The Headquarters Building
No.168 Tibet Road(M), Shanghai 200001
Tel: +86 21 2301 9800
Fax: +86 21 2301 9801 .................................................................................................. Guangzhou:
Rm1501, 15/F Jietai Plaza
218-222 Zhongshan Liu Lu, Guangzhou 510180, Guangdong
Tel: +86 21 8132 1880
Fax: +86 20 8132 1881 .................................................................................................. Chongqing:
Rm01A-03, 19/F Da Du Hui Building
68 Zourong Road, Yuzhong District, Chongqing 400010
Tel: +86 23 6382 5658
Fax: +86 23 6382 7618 .................................................................................................. GlaxoSmithKline HK:
23/F, Tower 6, The Gateway, 9 Canton Road
Tsimshatsui, Kowloon, Hong Kong
Tel: +852 3189 8989
Fax: +852 3189 8931 ..................................................................................................
Factories
................................................................................................................................................. Sino-American Tianjin SmithKline & French Labs Ltd.
Cheng Lin Zhuang Industrial District, Tianjin 300163
Tel: +86 22 2470 0888
Fax: +86 22 2470 0666 .................................................................................................. GlaxoSmithKline (Tianjin) Co., Ltd.
No.65, 5th Avenue, TEDA, Tianjin 300457
Tel: +86 22 6201 2222
Fax: +86 22 6201 7150 .................................................................................................. GlaxoSmithKline Pharmaceuticals (Suzhou) Ltd.
40# Su Hong Xi Road, Suzhou Industrial Park, Suzhou 215021
Tel: +86 512 6257 1660
Fax: +86 512 6257 0324 .................................................................................................. GlaxoSmithKline Biological Shanghai Ltd.
277 Newton Road, Zhangjiang High-tech Park, Pudong, Shanghai 201203
Tel: +86 21 5080 1010
Fax: +86 21 5080 1011
Company email
................................................................................................................................................. mail.2.china@gsk.com

 

 

 



AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.